Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Recruiting · NCT06228053 · Registry updated 2026-06-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Recruiting | Phase 2 | 2026-06-02 | NCT06228053 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
| Syntrix Biosystems, Inc. | 9 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke University | Durham | United States | 160 |
| University of California, Los Angeles | Los Angeles | United States | 142 |
| University of California, San Francisco | San Francisco | United States | 294 |
| University of Michigan | Ann Arbor | United States | 538 |
| University of Minnesota | Minneapolis | United States | 325 |
| University of Wisconsin | Madison | United States | 85 |